4 Research Drive
Woodbridge, CT 06525
AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases. AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule which works by inhibiting MEK Kinase, an important target implicated in various rare diseases including cancer. AlloMek plans to initiate clinical trials in rare diseases and the initial rare disease indication is Neurofibromatosis Type 1 (NF1) where CIP-137401 has shown excellent safety profile and robust activity in a preclinical pharmacology mouse model and exhibited a clear advantage over approved and experimental drugs. In additional to NF1, CIP-137401 has also demonstrated powerful proof of concept (POC) in a well-established mouse model of Emery-Dreifuss muscular dystrophy caused by LMNA gene mutations. Based on the mechanism, we also expect CIP-137401 to be effective in Noonan Syndrome, and in a variety of cancers.